Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients

American Journal of Geriatric Psychiatry

Volumn 11, Issue 2, 2003, Pages 179-185

  Landi, Francesco ^a   Cesari, Matteo ^a,b   Onder, Graziano ^a,b   Russo, Andrea ^a   Torre, Sergio ^a   Bernabei, Roberto ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID PROTEIN; DICLOFENAC; IBUPROFEN; KETOPROFEN; KETOROLAC; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

AGED; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; FEMALE; HOME CARE; HUMAN; INFLAMMATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUROPROTECTION; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PREVALENCE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; STATISTICAL ANALYSIS;

EID: 84903123397     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019442-200303000-00008     Document Type: Article

References (58)

1. Rogers J, Webster S, Lue LF, et al: Inflammation and Alzheimer's disease pathogenesis. Neurobiol Aging 1996; 5:681-686
2. McGeer PL, Rogers J: Anti-inflammatory agents as therapeutic approach to Alzheimer's disease. Neurology 1992; 42:447-449
3. Aisen PS, Davis KL: Inflammatory mechanisms in Alzheimer's disease: implication for therapy. Am J Psychiatry 1994; 151:1105-1113
4. McGeer PL, McGeer EG: The inflammatory response system of the brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brian Res Brian Res Rev 1995; 21:195-218
5. Finch C: Therapeutic targets in Alzheimer's disease: suggestions for the NIA. Neurobiol Aging 1994; 15(suppl2):S183-S185
6. O'Banion MK, Finch CE: Inflammatory mechanism and anti-inflammatory therapy in Alzheimer's disease. Neurobiol Aging 1996; 17:669-671
7. MacKenzie IRA: Anti-inflammatory drugs in the treatment of Alzheimer's disease. J Rheumatol 1996; 23:806-808
8. Stephenson J: More evidence links NSAID, estrogen use with reduced Alzheimer risk. JAMA 1996; 275:1389-1390
9. Schnabel J: New Alzheimer's therapy suggested. Science 1993; 260:1719-1720
10. Matsubara E, Hirai S. Amari M, et al: Alpha-1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. Ann Neurol 1990; 28:561-567
11. 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 1988; 52:487-601
12. Fillit H, Ding W, Buee L: Elevated circulating tumor necrosis factor levels in Alzheimer's disease. Neurosci Lett 1991; 129:318-320
13. Pasinetti GM: Inflammatory mechanisms in neurodegeneration and Alzheimer's disease: the role of the complement system. Neurobiol Aging 1996; 17:707-716
14. McGeer PL, Akiyama H, Itagaki S, et al: Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett 1989; 107:341-346
15. Jenkinson ML, Bliss MR, Brain AT, et al: Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br J Rheumatol 1989; 28:86-88
16. McGeer PL, McGeer E, Rogers J, et al: Anti-inflammatory drugs and Alzheimer disease (letter). Lancet 1990; 335:1037
17. Myllykangas-Luosujavarvi R, Isomaki H: Alzheimer's disease and rheumatoid arthritis. Br J Rheumatol 1994; 33:501-502
18. Broe GA, Henderson AS, Creasey H, et al: A case-control study of Alzheimer's disease in Australia. Neurology 1990; 40:1698-1707
19. Li G, Shen YC, Li YT, et al: A case-control study of Alzheimer's disease in China. Neurology 1992; 42:1481-1488
20. The Canadian Study of Health and Aging: Risk factors for Alzheimer's disease in Canada. Neurology 1994; 44:2073-2080
21. McGeer PL, Schulzer M, McGeer E: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996; 47:425-432
22. Breimer JCS, Gau BA, Welsh KA, et al: Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of co-twin control study. Neurology 1994; 44:227-232
23. Lucca U, Tettamenti M, Forloni G, et al: Nonsteroidal anti-inflammatory drug use in Alzheimer's disease. Biol Psychiatry 1994; 36:854-856
24. Andersen K, Launer LJ, Ott A, et al: Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 1995; 45:1441-1445
25. Rich JB, Rasmusson DX, Folstein MF, et al: Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995; 45:51-55
26. 2-blocking drugs. Neurobiol Aging 1995; 16:523-530
27. Rozzini R, Ferrucci L, Losonczv K, et al: Protective effect of chronic NSAID use on cognitive decline in older persons. J Am Geriatr Soc 1996; 44:1025-1029
28. Doraiswamy PM, Krishen A, Stallone F, et al: NSAIDs and cognition in Alzheimer's disease (letter). Neurology 1996; 46:1194
29. Stewart WF, Kawas C, Corrada M, et al: Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997; 48:626-632
30. Prince M, Rabe-Hesketh S, Brennan P: Do anti-arthritic drugs decrease the risk for cognitive decline? an analysis based on data from the MRC treatment trial of hypertension in older adults. Neurology 1998; 50:374-379
31. Mackenzie IRA, Munoz DG: Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 1998; 50:986-990
32. 't Veld BA, Ruitenberg A, Hofman A, et al: Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345:1515-1521
33. Rogers J, Kirby LC, Hempelman SR, et al: Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993; 43:1609-1611
34. Beard M, Waring SC, O'Brien PC, et al: Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin Proc 1998; 73:951-955
35. Stumer T, Glynn RJ, Field TS, et al: Aspirin use and cognitive function in the elderly. Am J Epidemiol 1996; 143:683-691
36. Broe GA, Grayson DA, Creasey HM, et al: Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 2000; 57:1586-1591
37. 2-receptor antagonists: The Cache County study. Neurology 2000; 54:2066-2071
38. Landi F, Lattanzio F, Gambassi G, et al: A model for integrated home care of frail older patients: The Silver Network Project. Aging Clin Exp Res 1999; 11:262-272
39. Morris JN, Fries BE, Steel K, et al: Comprehensive clinical assessment in community settings: applicability of the MDS-HC. J Am Geriatr Soc 1997; 45:1017-1024
40. Morris JN, Fries BE, Bernabei R, et al: RAI: Home Care Assessment Manual. InterRAI Corporation, Washington, DC, 1996
41. Landi F, Tua E, Onder G, et al: The Minimum Data Set for Home Care: a valid instrument to assess frail older people living in the community. Med Care 2000; 38:1184-1190
42. Hawes C, Morris JN, Phillips CD, et al: Reliability estimates of the Minimum Data Set (MDS) for nursing home resident assessment and care screening. Gerontologist 1995; 2:172-178
43. Landi F, Onder G, Cesari M, et al: Pain management in frail, community-living elderly patients. Arch Intern Med 2001; 161:2721-2724
44. Landi F, Onder G, Zuccalà G, et al: Non-scientific prescription in demented older people living in the community: an Italian perspective. Clinical Drug Investigation 2001; 21:157-160
45. Morris JN, Fries BE, Meher DR, et al: MDS Cognitive Performance Scale. J Gerontol 1994; 49:M174-M182
46. Hartmaier SL, Sloane PD, Guess HA, et al: Validation of the Minimum Data Set Cognitive Performance Scale: agreement with the Mini-Mental State Exam. J Gerontol 1995; 50:M128-M133
47. Frederiksen K, Tariot P, DeJonghe E: Minimum Data Set Plus (MDS +) scores compared with scores from five rating scales. J Am Geriatr Soc 1996; 44:305-309
48. Gambassi G, Lapane KL, Landi F, et al: Gender differences in the relation between comorbidity and mortality of patients with Alzheimer's disease. Systematic Assessment of Geriatric drug use via Epidemiology (SAGE) Study Group. Neurology 1999; 53:508-516
49. Lapane KL, Gambassi G, Landi F, et al: Gender differences in predictors of mortality in nursing home residents with Alzheimer's disease. Neurology 2001; 56:650-654
50. Saag KG, Rubenstein LM, Chrishilles EA, et al: Nonsteroidal anti-inflammatory drugs and cognitive decline in the elderly. J Rheumatol 1995; 22:2142-2147
51. Fourrier A, Letenneur L, Begaud B, et al: Nonsteroidal anti-inflammatory drug use and cognitive function in the elderly: inconclusive results from a population-based cohort study. J Clin Epidemiol 1996; 49:1201-1202
52. Handerson AS, Jorf AE Christensen H, et al: Aspirin, anti-inflammatory, drugs, and risk of dementia. Int J Geriatr Psychiatru 1997; 12:926-930
53. McGeer PL, McGeer EG: Inflammation, autotoxicity, and Alzheimet disease. Neurobiol Aging 2001; 22:799-809
54. Hawkey CJ: COX-2 inhibitors. Lancet 1999; 353:307-314
55. Pasinetti GM, Aisen PS: Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 1998; 87:319-324
56. Xiang Z, Ho L, Valdellon J, et al: Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol Aging 2002; 23:327-334
57. Breitner JCS, Zandi PP: Do nonsteroidal anti-inflammatory drugs reduce the risk of Alzheimer's disease? N Engl J Med 2001; 345:1568-1569
58. Zandi PP, Breitner JCS: Do NSAIDs prevent Alzheimer's disease? and, if so, why? the epidemiological evidence. Neurobiol Aging 2001; 22:811-817